US Stock MarketDetailed Quotes
ITRM Iterum Therapeutics
- 1.2550
- -0.0350-2.71%
Close Jul 24 16:00 ET
20.78MMarket Cap-475P/E (TTM)
1.3100High1.2200Low158.41KVolume1.3000Open1.2900Pre Close198.76KTurnover0.98%Turnover RatioLossP/E (Static)16.55MShares2.500052wk High-3.38P/B20.38MFloat Cap0.622052wk Low--Dividend TTM16.24MShs Float195.0000Historical High--Div YieldTTM6.98%Amplitude0.6010Historical Low1.2540Avg Price1Lot Size
Iterum Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -36.42%-13.08M | -112.91%-39.33M | -201.13%-12.84M | -104.12%-9.27M | -21.84%-7.63M | -181.64%-9.59M | -16.61%-18.47M | -73.44%-4.27M | -16.09%-4.54M | 24.90%-6.26M |
| Net income from continuing operations | 28.19%-7.1M | 13.64%-38.37M | -142.87%-12.36M | 86.68%-3.88M | -81.78%-12.24M | -182.54%-9.89M | 51.47%-44.43M | -21.71%-5.09M | -878.11%-29.11M | -186.37%-6.74M |
| Operating gains losses | -56.04%386K | -192.97%-11.06M | 110.30%305K | -159.50%-13.2M | 144.55%960K | 116.96%878K | -80.49%11.89M | 24.39%-2.96M | 330.46%22.18M | 86.23%-2.16M |
| Depreciation and amortization | -98.39%7K | -2.78%1.75M | 0.23%440K | -2.68%436K | -3.74%438K | -4.80%436K | -14.45%1.8M | -75.24%439K | 303.60%448K | 145.95%455K |
| Other non cash items | -5.11%1.25M | 10.44%5.95M | 188.60%2.08M | -2.11%1.3M | -14.17%1.26M | -29.84%1.31M | -33.86%5.38M | -50.58%719K | -49.75%1.33M | 50.26%1.47M |
| Change In working capital | -185.22%-7.76M | 19.56%2.76M | -197.54%-2.3M | 3,023.68%5.94M | 243.87%1.84M | -359.29%-2.72M | 625.23%2.31M | 1,319.17%2.35M | 108.31%190K | 42.04%-1.28M |
| -Change in prepaid assets | 115.64%226K | -105.54%-3.19M | -428.80%-628K | 144.95%169K | 17.00%-1.28M | -898.34%-1.45M | -253.87%-1.55M | 137.60%191K | 39.84%-376K | -50.34%-1.55M |
| -Change in payables and accrued expense | -516.39%-7.93M | 12.44%5.71M | -183.97%-1.81M | 371.38%5.77M | 178.99%3.04M | -309.27%-1.29M | 948.08%5.08M | 2,658.97%2.15M | 197.92%1.22M | 252.88%1.09M |
| -Change in other current assets | ---- | --322K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| -Change in other current liabilities | 1.96%-100K | 50.00%-354K | 2.00%-98K | 68.48%-52K | 62.08%-102K | 41.38%-102K | 36.33%-708K | 76.36%-100K | -5.77%-165K | -0.37%-269K |
| -Change in other working capital | -57.02%49K | 153.14%271K | -176.36%-84K | 110.77%53K | 133.87%188K | -73.30%114K | -288.19%-510K | -83.53%110K | -91.44%-492K | -177.50%-555K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -36.42%-13.08M | -112.91%-39.33M | -201.13%-12.84M | -104.12%-9.27M | -21.84%-7.63M | -181.64%-9.59M | -16.61%-18.47M | -73.44%-4.27M | -16.09%-4.54M | 24.90%-6.26M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 41.23%7.21M | 67.20%23.34M | 208.89%13.52M | -97.73%360K | 127.41%4.35M | -46.77%5.11M | 125.56%13.96M | 198.03%4.38M | 221.11%15.85M | 24.99%-15.86M |
| Net PPE purchase and sale | ---- | 79.03%-13K | --0 | 142.86%3K | ---- | ---- | -1.64%-62K | -246.15%-45K | 85.42%-7K | ---- |
| Net investment purchase and sale | 41.23%7.21M | 66.55%23.35M | 205.74%13.52M | -97.75%357K | 127.53%4.36M | -46.77%5.11M | 125.71%14.02M | 199.33%4.42M | 218.16%15.85M | 25.03%-15.85M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 41.23%7.21M | 67.20%23.34M | 208.89%13.52M | -97.73%360K | 127.41%4.35M | -46.77%5.11M | 125.56%13.96M | 198.03%4.38M | 221.11%15.85M | 24.99%-15.86M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 2,971.06%7.22M | 156.88%1.03M | 36.03%589K | 10K | 200K | 110.44%235K | -102.19%-1.82M | 126.58%433K | 0 | 0 |
| Net issuance payments of debt | ---- | --0 | --0 | --0 | ---- | ---- | 65.45%-2.25M | --0 | --0 | --0 |
| Net common stock issuance | 2,971.06%7.22M | 138.80%1.03M | 36.03%589K | --10K | --200K | --235K | -99.52%433K | --433K | --0 | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 2,971.06%7.22M | 156.88%1.03M | 36.03%589K | --10K | --200K | 110.44%235K | -102.19%-1.82M | 126.58%433K | --0 | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -71.10%6.11M | -23.21%21.13M | -76.40%4.85M | 48.47%13.77M | -46.33%16.87M | -23.21%21.13M | 85.68%27.51M | -42.98%20.55M | -74.71%9.27M | -52.91%31.43M |
| Current changes in cash | 131.65%1.35M | -136.19%-14.96M | 132.42%1.27M | -178.66%-8.9M | 86.06%-3.09M | -207.92%-4.25M | -149.91%-6.33M | 106.38%546K | 1,956.81%11.31M | 26.44%-22.13M |
| Effect of exchange rate changes | -125.00%-27K | -22.00%-61K | -151.85%-14K | 17.86%-23K | 55.56%-12K | 45.45%-12K | -1,350.00%-50K | 50.00%27K | -133.33%-28K | -775.00%-27K |
| End cash Position | -55.99%7.42M | -71.10%6.11M | -71.10%6.11M | -76.40%4.85M | 48.47%13.77M | -46.33%16.87M | -23.21%21.13M | -23.21%21.13M | -42.98%20.55M | -74.71%9.27M |
| Free cash flow | -36.42%-13.08M | -112.26%-39.34M | -197.98%-12.84M | -103.74%-9.26M | -21.90%-7.65M | -181.64%-9.59M | -16.55%-18.54M | -74.35%-4.31M | -14.86%-4.55M | 24.78%-6.27M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg